Loading...
XNAS
PCSA
Market cap5mUSD
Jul 14, Last price  
0.21USD
1D
-5.26%
1Q
-20.66%
IPO
-98.98%
Name

Processa Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
63.98%
Rev. gr., 5y
%
Revenues
0k
140,00020,000192,145312,480200,201113,4255,00000000000
Net income
-12m
L+6.55%
-160,000-940,000-2,440,538-3,068,701-4,526,250-3,354,227-335,982-1,856,315-3,765,047-3,357,876-14,413,788-11,427,534-54,848,458-11,121,520-11,850,118
CFO
-11m
L+39.46%
-160,000-710,000-1,886,500-2,538,769-2,695,448-871,906-43,203-1,654,617-3,707,914-2,750,145-3,143,196-8,717,291-9,605,143-8,063,346-11,245,042
Earnings
Aug 11, 2025

Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
IPO date
Oct 07, 2013
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
12,051
11,457
47,783
Unusual Expense (Income)
NOPBT
(12,051)
(11,457)
(47,783)
NOPBT Margin
Operating Taxes
27,424
Tax Rate
NOPAT
(12,051)
(11,457)
(75,207)
Net income
(11,850)
6.55%
(11,122)
-79.72%
(54,848)
379.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,747
6,321
(389)
BB yield
-267.58%
-1,440.46%
2.19%
Debt
Debt current
73
167
79
Long-term debt
74
217
380
Deferred revenue
Other long-term liabilities
Net debt
(1,044)
(4,321)
(6,045)
Cash flow
Cash from operating activities
(11,245)
(8,063)
(9,605)
CAPEX
(3)
(3)
Cash from investing activities
(3)
(3)
Cash from financing activities
7,733
6,269
(389)
FCF
(11,615)
(10,778)
(75,394)
Balance
Cash
1,191
4,706
6,504
Long term investments
Excess cash
1,191
4,706
6,504
Stockholders' equity
(87,219)
(75,369)
(64,246)
Invested Capital
88,989
80,592
71,946
ROIC
ROCE
EV
Common stock shares outstanding
3,276
1,312
16,109
Price
0.88
164.14%
0.33
-69.58%
1.10
-77.55%
Market cap
2,895
559.75%
439
-97.52%
17,720
-76.39%
EV
1,851
(3,883)
11,676
EBITDA
(12,050)
(11,457)
(46,994)
EV/EBITDA
0.34
Interest
101
Interest/NOPBT